Boule Diagnostics publishes the Annual Report for 2023

Boule Diagnostics AB has published the full Swedish Annual Report for the fiscal year 2023 at http://www.boule.com.

The annual report is available in English below as a PDF and in Swedish in the European Single Electronic Format (ESEF), printed copies will be available to shareholders upon request by late April.

For more information, please contact:

Torben Nielsen, CEO and Group President, Boule Diagnostics AB, torben.nielsen@boule.com
Holger Lembrér, CFO, Boule Diagnostics AB, phone. +46 (0)72-230 77 10, holger.lembrer@boule.com

About Boule Diagnostics AB (publ)
Boule Diagnostics AB (publ) is a global diagnostics company specializing in near-patient, decentralized blood diagnostics and one of the few companies in the global diagnostics market that conducts its own development, manufacturing and marketing of instruments and consumables for blood diagnostics. The Company primarily serves hospitals, clinics, laboratories and other diagnostics companies to which it offers complete systems for blood diagnostics (hematology) in both the human and veterinary areas. Boule has strong positions in important emerging markets such as in Asia and in recent years has improved its position in the fast-growing veterinary market. Operations are conducted through operating subsidiaries in Sweden, the United States, Mexico and Russia. The Group reported net sales of SEK 571 million in 2023 and has more than 200 employees. Sales are conducted globally, predominantly through the company’s 200 or so distributors in over 100 countries, supported by Boule’s own local sales and service personnel. Boule has been listed on Nasdaq Stockholm since 2011. http://www.boule.com

This information is information that Boule Diagnostics AB (publ) is obliged to make public pursuant to the Securities Market Act.
The information was submitted for publication, through the agency of the contact person set out above, at 11.00 CET on April 16, 2024.

Boule Annual Report 2023